Fosfomycin
Treatment for Urinary tract infections and interstitial nephritis
Typical Dosage: 3g single dose
Effectiveness
87%
Safety Score
70%
Clinical Trials
150
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
3g single dose
Time to Effect
1-2 days
Treatment Duration
single dose
Evidence Quality
MODERATENumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$45
Monitoring:$600
Side Effect Mgmt:$2
Total Annual:$647
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
Outcome-Based Costs
Cost per Responder
$55
Cost per Remission
$60
Prescription Access Economics
Annual Societal Loss per Patient
$160
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$150/year
Time Cost
$50/year
Travel + wait time
Insurance Admin Cost
$15/year
Prior auth, claims
Rx Price
$45/year
Potential OTC Price
$15/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
MODERATEFosfomycin Outcomes
for Urinary tract infections and interstitial nephritis
Efficacy Outcomes
Overall Effectiveness
+87%
Response Rate
+85%
Remission Rate
+78%
Common Side Effects
Diarrhea
+7%
Nausea
+3%
Headache
+2%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov